<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107937</url>
  </required_header>
  <id_info>
    <org_study_id>SOV01</org_study_id>
    <secondary_id>2013-001322-26</secondary_id>
    <nct_id>NCT02107937</nct_id>
  </id_info>
  <brief_title>Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma</brief_title>
  <official_title>A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotio a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotio a.s.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy
      (carboplatin plus paclitaxel as first line chemotherapy) may result in prolongation of
      progression free survival (PFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether DCVAC/OvCa added to Standard of Care
      chemotherapy (carboplatin plus paclitaxel as first line chemotherapy) may result in
      prolongation of progression free survival (PFS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall progression free survival (PFS)</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in remission after first line chemotherapy at 6 months</measure>
    <time_frame>0,10, 18, 30, 42 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in remission after first line chemotherapy at 12 months</measure>
    <time_frame>0,10, 18, 30, 42, 54, 68, 80, 92, 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological progression free interval</measure>
    <time_frame>0,10, 18, 30, 42, 54, 68, 80, 92, 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological Response</measure>
    <time_frame>0, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 54, 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring 2nd line chemotherapy</measure>
    <time_frame>0, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 21, 24, 27, 30, 36, 42, 48, 54, 60, 64, 68, 74, 80, 86, 92, 98, 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>0, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 21, 24, 27, 30, 36, 42, 48, 54, 60, 64, 68, 74, 80, 86, 92, 98, 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 50 percent survival</measure>
    <time_frame>0, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 21, 24, 27, 30, 36, 42, 48, 54, 60, 64, 68, 74, 80, 86, 92, 98, 104 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>DCVAC/OvCa with Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCVAC/OvCa in parallel with chemotherapy (Standard of Care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCVAC/OvCa sequentially chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCVAC/OvCa sequentially after chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standart of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/OvCa with Standard of Care</intervention_name>
    <description>DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel</description>
    <arm_group_label>DCVAC/OvCa with Standard of Care</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/OvCa sequentially chemotherapy</intervention_name>
    <description>DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel</description>
    <arm_group_label>DCVAC/OvCa sequentially chemotherapy</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy</description>
    <arm_group_label>Standart of Care</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged ≥18 years

          -  Patients with newly diagnosed, histologically confirmed, International Federation of
             Gynecology and Obstetrics (FIGO) stage III epithelial ovarian, primary peritoneal or
             fallopian tube carcinoma (serous, endometrioid or mucinous) who have undergone initial
             surgery up to 3 weeks before randomization and are selected to receive first line
             Standard of Care chemotherapy (optional prolongation to 6 weeks after surgery)

          -  Optimally debulked (zero residuum) or maximal residuum &lt;1cm

          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0,1,2

        Exclusion Criteria:

          -  FIGO I,II,IV epithelial ovarian cancer

          -  FIGO III clear cells epithelial ovarian cancer

          -  Non-epithelial ovarian cancer (OvCa), borderline tumors (tumors of low malignant
             potential)

          -  Post-surgery residual disease with lesion(s) &gt;1cm

          -  Prior or current systemic anti-cancer therapy for ovarian cancer [for example
             chemotherapy, monoclonal antibody therapy (bevacizumab), tyrosine kinase inhibitor
             therapy, vascular endothelial growth factor (VEGF) therapy or hormonal therapy]

          -  Previous or concurrent radiotherapy to the abdomen and pelvis

          -  Malignancy other than epithelial ovarian cancer, except those that have been in
             clinical remission (CR) for a minimum of 3 years, and except carcinoma in-situ of the
             cervix or non-melanoma skin carcinomas

          -  Patient co-morbidities:Human immunodeficiency virus (HIV) positive, human
             T-lymphotropic virus (HTLV) positive, Active hepatitis B (HBV), active hepatitis C
             (HCV), active syphilis

          -  Evidence of active bacterial, viral or fungal infection requiring systemic treatment

          -  Clinically significant cardiovascular disease including:

        Symptomatic congestive heart failure Unstable angina pectoris Serious cardiac arrhythmia
        requiring medication Uncontrolled hypertension Myocardial infarction or ventricular
        arrhythmia or stroke within a 6 month period before inclusion, ejection fraction (EF) &lt; 40
        percent or serious cardiac conduction system disorders, if a pacemaker is not present
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ales Horacek</last_name>
    <role>Study Director</role>
    <affiliation>Accord Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Kapsa</last_name>
    <phone>: (+420) 2241 74448</phone>
    <email>kapsa@sotio.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jihlava</city>
        <zip>586 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nový Jičín</city>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzeň</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ústí nad Labem</city>
        <zip>400 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>České Budějovice</city>
        <zip>370 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01465</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>serous</keyword>
  <keyword>endometrioid</keyword>
  <keyword>mucinous</keyword>
  <keyword>epithelial ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>EMA website</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

